Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Baculoviridae/*genetics ; Capsid Proteins/*genetics ; Oncogene Proteins, Viral/*genetics ; Papillomavirus Vaccines/*immunology ; Vaccines, DNA/*immunology; Animals ; Baculoviridae/immunology ; Endogenous Retroviruses/genetics ; Female ; Humans ; Mice ; Mice, Inbred BALB C ; Papillomaviridae/genetics ; Papillomaviridae/metabolism ; Papillomavirus Infections/immunology ; Papillomavirus Infections/prevention & control ; Papillomavirus Vaccines/administration & dosage ; Papillomavirus Vaccines/genetics ; Sf9 Cells ; Vaccination ; Vaccines, DNA/administration & dosage ; Vaccines, DNA/genetics
    • Abstract:
      Previously, we developed a non-replicating recombinant baculovirus coated with human endogenous retrovirus envelope protein (AcHERV) for enhanced cellular delivery of human papillomavirus (HPV) 16L1 DNA. Here, we report the immunogenicity of an AcHERV-based multivalent HPV nanovaccine in which the L1 segments of HPV 16, 18, and 58 genes were inserted into a single baculovirus genome of AcHERV. To test whether gene expression levels were affected by the order of HPV L1 gene insertion, we compared the efficacy of bivalent AcHERV vaccines with the HPV 16L1 gene inserted ahead of the 18L1 gene (AcHERV-HP16/18L1) with that of AcHERV with the HPV 18L1 gene inserted ahead of the 16L1 gene (AcHERV-HP18/16L1). Regardless of the order, the bivalent AcHERV DNA vaccines retained the immunogenicity of monovalent AcHERV-HP16L1 and AcHERV-HP18L1 DNA vaccines. Moreover, the immunogenicity of bivalent AcHERV-HP16/18L1 was not significantly different from that of AcHERV-HP18/16L1. In challenge tests, both bivalent vaccines provided complete protection against HPV 16 and 18 pseudotype viruses. Extending these results, we found that a trivalent AcHERV nanovaccine encoding HPV 16L1, 18L1, and 58L1 genes (AcHERV-HP16/18/58L1) provided high levels of humoral and cellular immunogenicity against all three subtypes. Moreover, mice immunized with the trivalent AcHERV-based nanovaccine were protected from challenge with HPV 16, 18, and 58 pseudotype viruses. These results suggest that trivalent AcHERV-HPV16/18/58L1 could serve as a potential prophylactic baculoviral nanovaccine against concurrent infection with HPV 16, 18, and 58.
    • References:
      PLoS One. 2013 Sep 18;8(9):e74797. (PMID: 24058629)
      Vaccine. 2006 Jun 12;24(24):5235-44. (PMID: 16675074)
      Trends Biotechnol. 2002 Apr;20(4):173-80. (PMID: 11906750)
      Int J Gynecol Cancer. 2008 Jan-Feb;18(1):71-9. (PMID: 17466054)
      J Med Virol. 1999 Oct;59(2):232-8. (PMID: 10459162)
      Cell Biosci. 2012 May 09;2(1):17. (PMID: 22571619)
      Expert Opin Ther Pat. 2011 Mar;21(3):295-309. (PMID: 21250872)
      Vaccine. 2004 Aug 13;22(23-24):3004-7. (PMID: 15297048)
      Biomaterials. 2011 Jul;32(20):4621-9. (PMID: 21440296)
      Expert Rev Vaccines. 2008 Sep;7(7):1085-101. (PMID: 18767956)
      Cell Mol Life Sci. 2001 Nov;58(12-13):1923-42. (PMID: 11766888)
      J Virol. 2002 Jun;76(11):5729-36. (PMID: 11992001)
      Vaccine. 2010 Apr 26;28(19):3479-87. (PMID: 20211219)
      Nat Rev Cancer. 2002 May;2(5):342-50. (PMID: 12044010)
      PLoS One. 2013 Nov 18;8(11):e80762. (PMID: 24260476)
      Clin Cancer Res. 2002 Dec;8(12):3676-85. (PMID: 12473576)
      Vaccine. 2006 Aug 31;24 Suppl 3:S3/26-34. (PMID: 16950015)
      J Infect Dis. 2009 Apr 1;199(7):919-22. (PMID: 19236278)
      Immunity. 2010 Oct 29;33(4):504-15. (PMID: 21029961)
      Vaccine. 2009 Sep 4;27(40):5450-9. (PMID: 19622402)
      Clin Infect Dis. 2011 Aug 1;53(3):296-302. (PMID: 21765081)
      J Virol. 2004 Jan;78(1):116-23. (PMID: 14671093)
      J Microbiol. 2012 Oct;50(5):813-20. (PMID: 23124750)
      Vaccine. 2010 Feb 10;28(6):1613-9. (PMID: 19961961)
      Vaccine. 2008 May 12;26(20):2451-6. (PMID: 18417258)
      Vaccine. 2009 May 29;27 Suppl 1:A46-53. (PMID: 19480962)
      Hum Gene Ther. 2012 Jul;23(7):733-41. (PMID: 22401308)
      Vaccine. 2010 Nov 10;28(48):7644-51. (PMID: 20883735)
      Int J Cancer. 2011 Jan 15;128(2):473-81. (PMID: 20309939)
      J Virol. 2006 Mar;80(6):2621-30. (PMID: 16501072)
      PLoS One. 2012;7(11):e50296. (PMID: 23209698)
      Lancet Oncol. 2012 Jan;13(1):100-10. (PMID: 22075170)
      Nat Med. 2007 Jul;13(7):857-61. (PMID: 17603495)
      Vaccine. 2011 Mar 3;29(11):2011-4. (PMID: 21241731)
      J Virol. 2004 Jan;78(2):751-7. (PMID: 14694107)
      Mol Cancer. 2011 Jan 07;10:3. (PMID: 21211062)
      Dermatology. 2004;209(3):218-22. (PMID: 15459536)
    • Accession Number:
      0 (Capsid Proteins)
      0 (HPV L1 protein, Human papillomavirus)
      0 (Oncogene Proteins, Viral)
      0 (Papillomavirus Vaccines)
      0 (Vaccines, DNA)
      6LTE2DNX63 (L1 protein, Human papillomavirus type 16)
      J2D279PEM5 (L1 protein, Human papillomavirus type 18)
    • Publication Date:
      Date Created: 20140425 Date Completed: 20150619 Latest Revision: 20211021
    • Publication Date:
      20231215
    • Accession Number:
      PMC3997520
    • Accession Number:
      10.1371/journal.pone.0095961
    • Accession Number:
      24759938